Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Inclusion Criteria: * Women who report elevated fatigue following cancer diagnosis and treatment Exclusion Criteria: * Women who have medical conditions that may affect the immune system or are associated with baseline fatigue syndrome, and/or who use medications that affect the immune system or fatigue. * Women with major affective disorders and those with sleep or pain disorders. * Presence of medical conditions that may but subject at undue risk for experimental procedures. * Chronic or recurring infections, symptoms of chronic heart failure, demyelinating disorders, and those taking immunosuppressive medications. * Neoplastic disease other than primary breast cancer * Compromised cardiovascular function * Insulin-dependent diabetes * Neurological disorder * Peripheral neuropathy * Pregnancy * Use of psychotropic medications within 2 weeks of screening * Abnormal screening laboratory findings (i.e., creatinine \> 1.4mg%; anemia; abnormal thyroid hormone; hematuria; elevated liver function tests, low protein or albumin; fasting glucose \>120mg%; elevated FTI or TSH; positive TB screening, HIV screening or hepatitis C). * Smokers